Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Real-time Estimate Cboe Europe Other stock markets 14:01:06 18/05/2026 BST			5-day change	1st Jan Change
287.80 ^DKK	-3.81%		-4.32%	-11.74%

05-15	European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading	MT
05-15	Sandoz Lands EU Nod for Insulin Biosimilars Bysumlog, Dazparda	MT

Transcript : Novo Nordisk A/S - Special Call

Published on 02/23/2026 at 11:50 am GMT - Modified on 02/23/2026 at 12:05 pm GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Novo Nordisk conference call. [Operator Instructions] Please be advised that today's conference

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Novo Nordisk A/S

05-15	European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading	MT
05-15	Sandoz Lands EU Nod for Insulin Biosimilars Bysumlog, Dazparda	MT
05-15	Baillie Gifford European repositions portfolio as asset value falls	AN
05-14	European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading	MT
05-13	Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring	RE
05-13	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of US-China Meeting	MT
05-13	Novo Nordisk Canada and Rexall Pharmacy partner to offer convenience, support, and home delivery for Canadians taking Ozempic and Wegovy	RE
05-13	Novo Nordisk Says Wegovy Pill Delivered Substantial Weight Loss, Mobility Improvement in Phase 3 Trial Analyses	MT
05-13	Novo Nordisk Pauses Manufacturing Plans at Odense Site, Layoff 150 Workers	MT
05-13	Denmark's Novo Nordisk Halts Development of Manufacturing Facility in Odense	MT
05-13	Novo Nordisk halts Odense construction and issues layoff notices	FW
05-13	Novo Nordisk Says Trial of Wegovy Pill Shows Some Patients Achieve Nearly 22% Weight Loss	DJ
05-13	Novo Nordisk says Wegovy pill delivers 21.6% weight loss in early responders	RE
05-13	NOVO NORDISK : Jefferies reaffirms its Neutral rating	ZD
05-13	Novo Nordisk: Oral Wegovy yields over 21 percent weight loss in clinical trial	FW